Jasper Bos, PhD is a General Partner at Forbion. He joined the CellCentric board in May 2025.
Jasper, a former Merck executive, joined Forbion as General Partner for the firm’s Growth Fund. Before joining Forbion’s Naarden-based headquarters, Jasper was Senior Vice President and Managing Director at M Ventures, the venture arm of pharmaceutical giant Merck, which he joined in 2009.
Under his leadership M Ventures invested in over 50 companies spanning biotech, life sciences tools, and tech companies with investment activities ranging from seed-stage to cross-over and IPO. His track record includes the successful sale of Prexton Therapeutics, Calypso, Epitherapeutics, Galecto, ObsEva, Translate Bio, and F-Star.
He has experience in several operational roles in portfolio companies and played a key role in the creation of multiple successful companies. Jasper was the Chief Executive Officer of Nasdaq-listed Forbion European Acquisition Company and currently represents Forbion on the Board of Directors of Anaveon, Engrail, and EnGene (“ENGN”). Jasper holds a PhD in Pharmacy from the University of Groningen, the Netherlands.
